Our Development Pipeline

In addition to our lead product candidates, Quilience and Nolazol, we have product candidates in their very early stages of development that we may or may not further develop. In addition to Quilience and Nolazol, we may seek to develop these other product candidates or other product candidates that are not currently in our pipeline in order to build a pipeline of product candidates at various stages of development that further complement our rare hypersomnia and complex neurodevelopmental disorder franchises. Additionally, we intend to continue to invest in our discovery research and development programs, with the goal of adding what we believe to be promising new compounds and indications to our product candidate development pipeline.